The FB23-everolimus combination synergistically inhibits pancreatic neuroendocrine tumors 15; similarly, the combination of FB23 and BX-912 targets FTO and the PDK1-AKT pathway to suppress breast cancer 16. The gene discussed is FTO; the disease is breast carcinoma.